Nestlé’s AI-Powered GLP-1 Foods Target Side Effect Challenges

Nestlé uses AI to develop affordable frozen meals for GLP-1 users, aiming to reduce nausea and other side effects that limit safe weight-loss drug access.

Nestlé employs AI tools to analyze 120,000 recipes and predict consumer responses, specifically targeting GLP-1 medication users with affordable frozen foods under its Vital Pursuit brand. This follows Innova Market Insights reports that 10% of U.S. adults used GLP-1 medications in 2024, rising to 18% by 2025. GLP-1 users consume 40% more protein and 30% more fiber than non-users but experience 25-40% muscle mass loss over 8-16 months. The company’s approach addresses a key barrier: nausea and other side effects that prevent safe long-term use of these drugs. By creating nutrient combinations that reduce adverse reactions, Nestlé aims to expand access to GLP-1 therapies without compromising nutritional needs.

This matters for food access because GLP-1 medications are increasingly used for weight management, yet their side effects often force users to avoid meals or supplements. Nestlé’s focus on affordable, AI-designed frozen meals could help maintain dietary quality while reducing nausea, potentially allowing more people to safely use these drugs.

What to watch: JP Morgan projects GLP-1 medications could reduce food and drink industry revenue by $30-55 billion by 2034, but current usage figures apply only to U.S. adults. Muscle mass decline and the 30 million U.S. user projection by 2030 (tripling current levels) require careful monitoring to ensure nutritional balance.

Source: Green Queen